Interview: “We need chemotherapy when rapid responses are required”
As the relative importance of chemotherapy in NSCLC management is changing, how can chemotherapeutic agents contribute to increasing efficacy in the context of new treatments?
Anti-angiogenic combinations excel in later lines
The ongoing, prospective, non-interventional VARGADO study is assessing the angiokinase inhibitor nintedanib plus docetaxel in patients with advanced adenocarcinoma of the lung after first-line chemotherapy in routine clinical practice. VARGADO is conducted at approximately 100 sites across Germany and includes 3 cohorts.
Interview: “We need chemotherapy when rapid responses are required”
As the relative importance of chemotherapy in NSCLC management is changing, how can chemotherapeutic agents contribute to increasing efficacy in the context of new treatments?
Extensive-disease small-cell tumors: signals of activity
Most of the patients with small-cell lung cancer (SCLC) are diagnosed in the extensive-disease stage (ED-SCLC). They generally respond well to first-line platinum-based chemotherapy; however, responses are not durable, and prognosis is poor. In the second line and beyond, the NCCN guidelines recommend patient inclusion in a clinical trial, systemic therapy depending on the patient performance status and the duration of the relapse-free interval, or palliative symptom management.
Interview: Improving accuracy of lung cancer screening
Interview: Improving accuracy of lung cancer screenin ...
Encouraging findings in NTRK-, ROS1– and ALK-positive lung cancer
Encouraging findings in NTRK-, ROS1– and ALK-positive ...
Immunotherapy: analyses elucidating durvalumab & pembrolizumab activity
Immunotherapy: analyses elucidating durvalumab & ...
Current perspectives in EGFR-targeted therapy
Current perspectives in EGFR-targeted therapy Glo ...
Preface – ELCC 2019
Preface – ELCC 2019 Pilar Garrido, MD, PhD Head o ...
